BioCentury
ARTICLE | Clinical News

Vatreptacog alfa: Development discontinued

October 1, 2012 7:00 AM UTC

Novo Nordisk discontinued development of vatreptacog alfa after data from the double-blind, international Phase IIIa adept 2 trial in 72 patients with congenital hemophilia and inhibitors showed that ...